<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623894</url>
  </required_header>
  <id_info>
    <org_study_id>GRS 1193/B/15</org_study_id>
    <nct_id>NCT02623894</nct_id>
  </id_info>
  <brief_title>Influence of Different Risk Factors in Vascular Accelerated Aging (EVA Study)</brief_title>
  <official_title>Influence of Different Risk Factors in Vascular Accelerated Aging. A Cross-sectional, Descriptive Observational Study (EVA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion y Formacion en Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Castilla-León Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Investigacion y Formacion en Ciencias de la Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: The process of population aging that is occurring in developed societies&#xD;
      represents a major challenge for the health system. The aim of this study is to analyze&#xD;
      factors that have an influence on early vascular aging (EVA), estimated by carotid-femoral&#xD;
      pulse wave velocity (cf-PWV) and Cardio Ankle Vascular Index (CAVI), and to determine&#xD;
      differences by gender in a Spanish population.&#xD;
&#xD;
      Methods and analysis: An observational, descriptive, cross sectional study.&#xD;
&#xD;
      Study Population: From the population assigned to the participating Health Care centers, a&#xD;
      cluster random sampling stratified by age and gender will be performed to obtain 500&#xD;
      participants aged between 35 and 75. Those who meet the inclusion criteria and give written&#xD;
      informed consent will be included in the study.&#xD;
&#xD;
      Measurements: Main dependent variables: cf-PWV determined using Sphigmo Cor System and CAVI&#xD;
      estimated using VASERA. Secondary dependent variables: telomere length, carotid intima-media&#xD;
      thickness, central and peripheral augmentation index, ankle-brachial pulse wave velocity,&#xD;
      ankle-brachial index, retinal arteriovenous index, and renal and cardiac organ damage.&#xD;
      Independent variables: Lifestyles (physical activity, adherence to mediterranean diet,&#xD;
      alcohol and tobacco consumption); psychological factors (depression, anxiety, and chronic&#xD;
      stress); inflammatory factors and oxidative stress.&#xD;
&#xD;
      Ethics and dissemination: The study has been approved by the clinical research ethics&#xD;
      committee of the healthcare area of Salamanca. All study participants will sign an informed&#xD;
      consent to agree to participate in the study in compliance with the Declaration of Helsinki&#xD;
      and the WHO standards for observational studies. The results of this study will allow the&#xD;
      understanding of the relationship of the different influencing factors and their relative&#xD;
      weight in the development of EVA. At least five publications in first-quartile scientific&#xD;
      journals are planned.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The general objectives of this study are: To establish reference values for vascular&#xD;
      structure and function in the population of Salamanca.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A cross-sectional, descriptive observational study. The investigators consider subjects with&#xD;
      EVA as those having cf-PWV and/or CAVI values greater than the 75th percentile.&#xD;
&#xD;
      Study setting:&#xD;
&#xD;
      To be implemented in the Research Unit of La Alamedilla Primary Care Center, and on the&#xD;
      premises of the Hospital and University of Salamanca of the eight participating groups from&#xD;
      the Biomedical Research Institute of Salamanca (IBSAL).&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      It will be the urban population attached to the Health Center of Salamanca. Using a random&#xD;
      sampling stratified by age groups (35, 45, 55, 65 and 75 years) and gender, 100 subjects will&#xD;
      be selected in each group (50 males and 50 females), aged 35 to 75 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Cardio-ankle vascular index</measure>
    <time_frame>2 years</time_frame>
    <description>This parameter will be estimated using Vasera device VS-1500.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brachial-ankle pulse wave velocity (ba-PWV)</measure>
    <time_frame>2 years</time_frame>
    <description>This parameter will be estimated using Vasera device VS-1500.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-brachial index</measure>
    <time_frame>2 years</time_frame>
    <description>This parameter will be estimated using Vasera device VS-1500.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central augmentation index</measure>
    <time_frame>2 years</time_frame>
    <description>This parameter will be estimated using the Sphygmo Cor System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Intima Media Thickness</measure>
    <time_frame>2 years</time_frame>
    <description>A Sonosite Micromax ultrasound device paired with a 5-10 MHz multifrequency high-resolution linear transducer with Sonocal software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of retinal vessels</measure>
    <time_frame>2 years</time_frame>
    <description>Retinography will be performed using a Topcon TRC NW 200 non-mydriatic retinal camera (Topcon Europe B.C., Capelle a/d Ijssel, The Netherlands), obtaining nasal and temporal images centered on the disk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the mediterranean diet</measure>
    <time_frame>2 years</time_frame>
    <description>Principal endpoint of alimentation, will be measured using the validated 14-point Mediterranean Diet Adherence Screener.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective measure of physical activity</measure>
    <time_frame>2 years</time_frame>
    <description>It will be measured using Actigraph GT3X accelerometers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported physical activity</measure>
    <time_frame>2 years</time_frame>
    <description>It will be measured using the International Physical Activity Questionnaire - Short Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedentary time</measure>
    <time_frame>2 years</time_frame>
    <description>It will be measured using the Questionnaire hours seated (Marshall).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective assessment of physical activity</measure>
    <time_frame>2 years</time_frame>
    <description>It will be measured using the Paffenbarger Physical Activity Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid-femoral pulse wave velocity</measure>
    <time_frame>2 years</time_frame>
    <description>This parameter will be estimated using the Sphygmo Cor System.</description>
  </secondary_outcome>
  <enrollment type="Actual">500</enrollment>
  <condition>Healthy</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fasting plasma glucose, creatinine, uric acid, Ca, P, serum total cholesterol, high-density&#xD;
      lipoprotein cholesterol and triglyceride levels will be measured using standard enzymatic&#xD;
      automated methods. Low-density lipoprotein cholesterol will be estimated by the Friedewald&#xD;
      equation when the direct parameter is not available. Glycated haemoglobin will be measured&#xD;
      with an immune-turbidimetric assay. Cytokines concentrations in plasma will be determined by&#xD;
      ELISA using commercial kits and following the manufacturer's recommendations. Oxidative&#xD;
      stress will be determined by measuring lipid peroxides and nucleic acid derivatives by ELISA&#xD;
      using commercial kits and following the manufacturer's recommendations.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population It will be the urban population attached to the Health Center of&#xD;
        Salamanca. Using a random sampling stratified by age groups (35, 45, 55, 65 and 75 years)&#xD;
        and gender, 100 subjects will be selected in each group (50 males and 50 females), aged 35&#xD;
        to 75 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 35 to 75 years who agree to participate in the study and do not meet any&#xD;
             of the exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are in terminal condition, who cannot travel to the health centers to&#xD;
             undergo the corresponding examinations, and those who do not wish to sign the informed&#xD;
             consent.&#xD;
&#xD;
          -  Subjects with a history of CVD (ischemic heart disease or stroke, peripheral arterial&#xD;
             disease or heart failure), diagnosed renal failure in terminal stages (glomerular&#xD;
             filtration rate below 30%), chronic inflammatory disease, or acute inflammatory&#xD;
             process in the past three months.&#xD;
&#xD;
          -  Patients treated with estrogens, testosterone, or growth hormone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Primary care Research unit. La Alamedilla health centre</name>
      <address>
        <city>Salamanca</city>
        <zip>37003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manuel A Gómez Marcos</name>
      <address>
        <city>Salamanca</city>
        <zip>37006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Gomez-Marcos MA, Martinez-Salgado C, Gonzalez-Sarmiento R, Hernandez-Rivas JM, Sanchez-Fernandez PL, Recio-Rodriguez JI, Rodriguez-Sanchez E, García-Ortiz L. Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study. BMJ Open. 2016 Jun 7;6(6):e011031. doi: 10.1136/bmjopen-2016-011031.</citation>
    <PMID>27267107</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular aging.</keyword>
  <keyword>Arterial stiffness.</keyword>
  <keyword>Lifestyles.</keyword>
  <keyword>Vascular structure.</keyword>
  <keyword>Telomere length,</keyword>
  <keyword>Psychological factors.</keyword>
  <keyword>Inflammatory factors.</keyword>
  <keyword>Oxidative stress</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

